Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniela Russo
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0001-9471-1935
Observed ORCID:
0000-0001-9471-1935
OpenAlex ID:
A5123881890
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells
2026
·
Federica Auletta
, Caterina Ieranò
, et al.
·
Cell Death Discovery
·
1
PDF
Figure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Data from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Show more works
View as search
Works count:
8
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type